These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35682838)

  • 1. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of In-Frame Deletion, Homology-Directed Repair, and Prime Editing-Based Correction of Duchenne Muscular Dystrophy Mutations.
    Zhao X; Qu K; Curci B; Yang H; Bolund L; Lin L; Luo Y
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
    Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
    Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
    Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
    Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
    Wang DN; Wang ZQ; Jin M; Lin MT; Wang N
    Gene Ther; 2022 Dec; 29(12):730-737. PubMed ID: 35534612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.
    Dhoke NR; Kim H; Azzag K; Crist SB; Kiley J; Perlingeiro RCR
    Cells; 2024 Jun; 13(11):. PubMed ID: 38891104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
    Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
    Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 17. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
    Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
    Gene; 2023 May; 867():147358. PubMed ID: 36914142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in
    Happi Mbakam C; Rousseau J; Lu Y; Bigot A; Mamchaoui K; Mouly V; Tremblay JP
    Mol Ther Nucleic Acids; 2022 Dec; 30():272-285. PubMed ID: 36320324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.